Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET/CT Assessment

NCT06563245 is registered in ClinicalTrials.gov with Children's Cancer Group, China as lead sponsor.

NCT NCT06563245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06563245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET/CT Assessment
Lead sponsor
Children's Cancer Group, China
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 25, 2024
Completion date
November 15, 2039
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adolescent, brentuximab vedotin, child, classical hodgkin lymphoma, metabolic response, pet scan, survival, treatment, young adult